Our Team

Extensive expertise in drug development and commercialization in immunotherapy, immunology, and oncology

ImmunOs Therapeutics AG,  a spin-off of the University of Zurich and University of Basel, is leading the discovery and development of the next generation of novel human immunomodulatory proteins for cancer treatment that not only have direct anti-tumor effects but also remodel the tumor microenvironment and enhance the efficacy of existing immunotherapies. The team has extensive expertise in the field of drug development and global commercialization in immunotherapy, immunology, and oncology

Dr. Darryl H. Patrick, DVM, PhD

Head of Nonclinical Development

Pharmaceutical Research and Development Executive specializing in Nonclinical Development for over 30 years. Began at Merck/MSD Research Laboratories serving in numerous roles over 20 years ultimately serving as Vice President/Head, Worldwide Safety Assessment responsible for all nonclinical aspects for potential drug development candidates, including toxicologic evaluation, defining preclinical drug development candidate plans, interacting with drug development teams, preparation of regulatory submissions including INDs/NDAs,. Subsequently, was Vice President, Exploratory Development at Vertex Pharmaceuticals responsible for all nonclinical development activities and Clinical Pharmacology directing programs through to proof of concept. While at Vertex, was member of management team responsible for first NCE developed within the Company.

Sean R. Smith

Chief Executive Officer of ImmunOs Therapeutics AG

Mr. Smith has served as CEO and a member of the Board of Directors for ImmunOs Therapeutics AG since May of 2017.  Mr. Smith previously spent over 15 years at MSD/Merck and Co., Inc in positions of increasing responsibility in commercial leadership, cross-departmental management, business development, country, and regional operations with broad exposure to multiple therapeutic areas including early-stage clinical, in-line, and launch portfolios in Hospital/Specialty, Infectious Disease, General Medicine, and Vaccines. He has extensive leadership experience in global markets focused in North America, Europe, Asia-Pacific, China, Japan, and Latin America. Mr. Smith received his B.S. from Pennsylvania State University and M.B.A. from the University of Denver​

Dr. Osiris Marroquin Belaunzaran

Chief Scientific Officer & Cofounder of ImmunOs Therapeutics AG

Over 13 years of research and development experience in immuno-oncology and autoimmunity leading various programs in product development for immuno-oncology therapeutics and expertise across multiple areas of drug discovery, drug delivery systems, protein engineering, antibody development, and pre-clinical development of therapeutics in diverse animal models of cancer, autoimmunity, and neurology. His extensive work led to multiple discoveries of a novel class of human immunomodulatory agents for treating cancer and infectious diseases.  He has a Ph.D. in Bioengineering and Biotechnology from EPFL Lausanne, Switzerland

Prof. Dr. med Christoph Renner

CHIEF MEDICAL OFFICER & Cofounder of ImmunOs Therapeutics AG

Professor of Medical Oncology at the University of Basel. Previous appointments included Head of the Department of Internal Medicine and Oncology, Head of the Cancer Center, Head of the division of Clinical Immunology and Professor for Clinical and Experimental Oncology at the University of Zurich. Prof. Dr. Renner joined the Swiss Tumor Institute in January 2013 and started a Cancer Center Initiative Network. He has a strong background in antibody engineering and was an affiliate of the Ludwig Institute for Cancer Research for more than 15 years and a senior physician specialist in Oncology, Onco-immunology and Internal Medicine at Hirslanden Hospital Zurich.  CR is a member of different research organizations and has served for six years on the board of the Swiss Group for Clinical Cancer Research. CR is currently consulting for four biotech companies as a scientific advisor with one being listed on the NASDAQ exchange  

Our mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease​